13:54:36 EDT Sat 20 Jul 2019
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Cipher Pharmaceuticals Inc
Symbol C : CPH
Shares Issued 26,829,054
Close 2019-03-25 C$ 1.47
Recent Sedar Documents

Cipher Pharmaceuticals appoints Mull to board

2019-03-26 07:31 ET - News Release

Mr. Mark Beaudet reports

CIPHER PHARMACEUTICALS APPOINTS MR. CRAIG MULL TO THE BOARD OF DIRECTORS

Craig Mull has been appointed as a member of Cipher Pharmaceuticals Inc.'s board of directors, effective immediately.

Mr. Mull is the managing director of 1207407 Ontario Ltd. and is responsible for overseeing a variety of investments including the company's shareholding in Cipher. Mr. Mull is also the founder and chief executive officer of the Typhon Group Ltd., a privately held real estate development firm which owns and develops commercial and residential projects throughout the Greater Toronto Area.

Mr. Mull has extensive experience in the Canadian health care industry, including holding the position of chief operating officer with CML HealthCare where he was responsible for the day-to-day operations. During his tenure at CML, Mr. Mull was part of a small executive team that grew the company from a market cap of $100-million to over $1.2-billion.

Mr. Mull also played an integral role in planning and structuring Cipher's initial public offering as it was spun out of CML.

"We are pleased to welcome Craig to the Cipher board of directors," said Mark Beaudet, chair of Cipher's board of directors. "Craig has known Cipher since its initial public offering and adds transaction experience to Cipher's board of directors."

Mr. Mull commented: "I'm excited to join the board at this important stage in the company's evolution. I look forward to assisting the team, as we continue to identify growth opportunities that enhance shareholder value."

About Cipher Pharmaceuticals Inc.

Cipher is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early- to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America.

© 2019 Canjex Publishing Ltd. All rights reserved.